Abstract
Chagas disease (CD) caused by Trypanosoma cruzi remains a Neglected Tropical Disease with limited access to diagnosis and treatment, particularly for chronically infected patients. Clinical trials are underway to improve treatment using new drugs or different regimens, and Real-Time PCR is used to assess the parasitological response as a surrogate biomarker. However, PCR-based strategies have limitations due to the complex nature of T. cruzi infection. The parasite exhibits asynchronous replication, different strains and clones, and diverse tissue tropism, making it challenging to determine optimal timeline points for monitoring treatment response. This mini-review explores factors that affect PCR-based monitoring and summarizes the endpoints used in clinical trials for detecting treatment failure. Serial sampling and cumulative PCR results may improve sensitivity in detecting parasitemia and treatment failure in these trials.
Reference46 articles.
1. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia;Alonso-Vega;BMJ Open,2021
2. Efficacy and safety of nifurtimox in pediatric patients with chagas disease: results at 4-year follow-up in a prospective, historically controlled study (CHICO SECURE);Altcheh;Antimicrob. Agents Chemother.,2023
3. Protozoan persister-like cells and drug treatment failure;Barrett;Nat. Rev. Microbiol.,2019
4. Analytical sensitivity and specificity of a loop-mediated isothermal amplification (LAMP) kit prototype for detection of trypanosoma cruzi DNA in human blood samples;Besuschio;PloS Negl. Trop. Dis.,2017
5. Trypanosoma cruzi loop-mediated isothermal amplification (Trypanosoma cruzi loopamp) kit for detection of congenital, acute and chagas disease reactivation;Besuschio;PloS Negl. Trop. Dis.,2020